Welcome to LookChem.com Sign In|Join Free

CAS

  • or

203922-25-2

Post Buying Request

203922-25-2 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

203922-25-2 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 203922-25-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,0,3,9,2 and 2 respectively; the second part has 2 digits, 2 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 203922-25:
(8*2)+(7*0)+(6*3)+(5*9)+(4*2)+(3*2)+(2*2)+(1*5)=102
102 % 10 = 2
So 203922-25-2 is a valid CAS Registry Number.

203922-25-2Downstream Products

203922-25-2Relevant articles and documents

New generation dopaminergic agents. 6. Structure-activity relationship studies of a series of 4-(aminoethoxy)indole and 4-(aminoethoxy)indolone derivatives based on the newly discovered 3-hydroxyphenoxyethylamine D2 template

Mewshaw, Richard E.,Webb, Michael B.,Marquis, Karen L.,McGaughey, Georgia B.,Shi, Xiaojie,Wasik, Theodore,Scerni, Rosemary,Brennan, Julie A.,Andree, Terrance H.

, p. 2007 - 2020 (2007/10/03)

A series of 4-(aminoethoxy)indoles 7 and a related series of 4- (aminoethoxy)indolones 8 were synthesized and evaluated for their affinity for both the high- and low-affinity agonist states (D2(High) and D2(Low), respectively) of the dopamine (DA) D2 receptor. The 4-aminoethoxy derivatives (i.e., 7 and 8) were designed as bioisosteric analogues based on the phenol prototype 4. The indolones 8 were observed to have high affinity for the D2(High) receptor. Comparison of their previously reported chroman analogues with the more flexible 4-(aminoethoxy)indoles revealed the chroman analogues to be more potent, whereas little loss in D2(High) affinity was observed when comparing the 4-(aminoethoxy)indolones with their respective chroman analogues. Several regions of the phenoxyethylamine framework were modified and recognized as potential sites to modulate the level of intrinsic activity. A conformational analysis was performed and a putative bioactive conformation was proposed which fulfilled the D2 agonist pharmacophore criteria based on the McDermed model. Structure-activity relationships gained from these studies have aided in the synthesis of D2 partial agonists of varying intrinsic activity levels. These agents should be of therapeutic value in treating disorders resulting from hypo- and hyperdopaminergic activity, without the side effects associated with complete D2 agonism or antagonism.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 203922-25-2